our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells

News alerts, weekly reports and conference planners

Company:

SZGIMI

Drug class:

CD123-targeted CAR-T immunotherapy, MUC1-targeted CAR-T immunotherapy, CD33-targeted CAR-T immunotherapy, CD38-targeted CAR-T immunotherapy, CD56-targeted CAR-T immunotherapy, CLL-1-targeted CAR-T immunotherapy

Related drugs:

‹

anti-CD56-CAR-T (0)

CB-012 (0)

CD371-YSNVZ-IL18 CAR T cells (0)

KITE-222 (0)

UCART123 (2)

ACLX-002 (1)

4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR (0)

4SCAR-T (0)

AVC-101 (0)

AVC-201 (0)

Autologous CAR-T cells (0)

CART123 (0)

CD123 CAR-T cell therapy (0)

CD123-CAR T cell therapy (0)

EQ (0)

CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells (0)

CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T (0)

GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)

Tn MUC1 CAR T-cell therapy (0)

anti-MUC1 CAR-T cells (0)

huMNC2-CAR22 (0)

huMNC2-CAR44 CAR T cells (0)

Dual CD33/CLL1 CAR T (0)

multi-target gene-modified CAR-T/TCR-T cell immunotherapy (0)

CART-38 (0)

anti-CD56-CAR-T (0)

CB-012 (0)

CD371-YSNVZ-IL18 CAR T cells (0)

KITE-222 (0)

›

19d

Multi-CAR T Cell Therapy for Acute Myeloid Leukemia (clinicaltrials.gov)

P1/2, N=10, Recruiting, Shenzhen Geno-Immune Medical Institute | Unknown status --> Recruiting | Trial completion date: Dec 2020 --> Dec 2028 | Trial primary completion date: Dec 2019 --> Jun 2028

19 days ago

Enrollment open • Trial completion date • Trial primary completion date

CD38 (CD38 Molecule) • CD33 (CD33 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • IL3RA (Interleukin 3 Receptor Subunit Alpha)

Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells